• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

由新型冠状病毒肺炎（COVID-19）导致的高凝状态引发即将发生的股青肿和亚大面积双侧肺栓塞。

Hypercoagulability Due to COVID-19 Leading to Impending Phlegmasia Cerulea Dolens and Sub-Massive Bilateral Pulmonary Embolism.

作者信息

Moraes Bruno, Hashemi Amir, Mancheno Kevin, ObanDo Manuel, Marra Erin

机构信息

Emergency Medicine, Graduate Medical Education, Aventura Hospital and Medical Center, Aventura, USA.

Emergency Medicine, Nova Southeastern University, Dr. Kiran C. Patel College of Allopathic Medicine, Aventura, USA.

出版信息

Cureus. 2021 Aug 21;13(8):e17351. doi: 10.7759/cureus.17351. eCollection 2021 Aug.

DOI:10.7759/cureus.17351
PMID:34567892
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8451714/
Abstract

This is a case report of a 47-year-old male with a history of hypertension and pre-diabetes who presented to the emergency department with dyspnea, progressive unilateral leg swelling and pain. The patient tested positive for coronavirus disease 2019 (COVID-19) infection about a week earlier. The patient was found to have an extensive clot burden of his lower extremity veins, both deep and superficial, which extended to his inferior vena cava (IVC). Based on the patient's clinical exam and ultrasound findings, the patient was diagnosed with impending phlegmasia cerulea dolens. Due to his renal failure, the patient was taken for a ventilation/perfusion (V/Q) scan which found widespread V/Q mismatch highly suggestive of pulmonary embolism. Interventional radiology took the patient for lower extremity venogram, catheter-directed alteplase administration, and IVC filter placement. The patient was admitted to the intensive care unit (ICU) for further management and had a stable recovery.

摘要

这是一例47岁男性的病例报告，该患者有高血压和糖尿病前期病史，因呼吸困难、单侧下肢进行性肿胀和疼痛就诊于急诊科。患者大约一周前新型冠状病毒肺炎（COVID-19）感染检测呈阳性。发现患者下肢静脉（包括深静脉和浅静脉）有广泛的血栓负荷，血栓延伸至下腔静脉（IVC）。根据患者的临床检查和超声检查结果，患者被诊断为即将发生的股青肿。由于患者存在肾衰竭，对其进行了通气/灌注（V/Q）扫描，结果发现广泛的V/Q不匹配，高度提示肺栓塞。介入放射科医生为患者进行了下肢静脉造影、导管定向阿替普酶给药和下腔静脉滤器置入术。患者被收入重症监护病房（ICU）进行进一步治疗，并恢复稳定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5684/8451714/1191fcb13f81/cureus-0013-00000017351-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5684/8451714/316197bcad14/cureus-0013-00000017351-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5684/8451714/255cd18327f7/cureus-0013-00000017351-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5684/8451714/8e914a814118/cureus-0013-00000017351-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5684/8451714/1e077edee3c7/cureus-0013-00000017351-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5684/8451714/1191fcb13f81/cureus-0013-00000017351-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5684/8451714/316197bcad14/cureus-0013-00000017351-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5684/8451714/255cd18327f7/cureus-0013-00000017351-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5684/8451714/8e914a814118/cureus-0013-00000017351-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5684/8451714/1e077edee3c7/cureus-0013-00000017351-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5684/8451714/1191fcb13f81/cureus-0013-00000017351-i05.jpg

相似文献

1
Hypercoagulability Due to COVID-19 Leading to Impending Phlegmasia Cerulea Dolens and Sub-Massive Bilateral Pulmonary Embolism.由新型冠状病毒肺炎（COVID-19）导致的高凝状态引发即将发生的股青肿和亚大面积双侧肺栓塞。
Cureus. 2021 Aug 21;13(8):e17351. doi: 10.7759/cureus.17351. eCollection 2021 Aug.
2
COVID-19-Induced Phlegmasia Cerulea Dolens.新型冠状病毒肺炎所致股青肿
Cureus. 2023 Jan 11;15(1):e33644. doi: 10.7759/cureus.33644. eCollection 2023 Jan.
3
Compartment syndrome in patients with massive venous thrombosis after inferior vena cava filter placement.下腔静脉滤器置入术后大量静脉血栓形成患者的骨筋膜室综合征
Orthopedics. 2011 Mar 11;34(3):229. doi: 10.3928/01477447-20110124-23.
4
Phlegmasia cerulea dolens: rare complication of vena cava filter placement in man with paraplegia.股青肿：截瘫男性患者放置腔静脉滤器后的罕见并发症。
J Spinal Cord Med. 2008;31(4):398-402. doi: 10.1080/10790268.2008.11760743.
5
Successful Intravascular Ultrasound-Guided Thrombus Removal and Angioplasty for Phlegmasia Cerulea Dolens in a Young Male With a History of Multiple Lower Extremity Deep Vein Thrombosis.血管内超声引导下成功清除血栓及血管成形术治疗一名有多次下肢深静脉血栓形成病史的年轻男性的股青肿
Cureus. 2023 May 30;15(5):e39739. doi: 10.7759/cureus.39739. eCollection 2023 May.
6
Successful treatment of posttraumatic phlegmasia cerulea dolens by reconstructing the external iliac vein: a case report.通过重建髂外静脉成功治疗创伤后股青肿：一例报告
J Med Case Rep. 2014 May 14;8:149. doi: 10.1186/1752-1947-8-149.
7
An Uncommon Cause of Shock: Acute Thrombosis of the Inferior Vena Cava.一种不常见的休克原因：下腔静脉急性血栓形成。
J Emerg Med. 2021 Jul;61(1):67-69. doi: 10.1016/j.jemermed.2021.02.027. Epub 2021 May 8.
8
Rare Case of Unilateral Phlegmasia Cerulea Dolens With Bilateral Deep Vein Thrombosis at a Community Military Hospital Emergency Department.社区军事医院急诊科单侧股青肿合并双侧深静脉血栓形成的罕见病例
Mil Med. 2017 May;182(5):e1823-e1825. doi: 10.7205/MILMED-D-16-00346.
9
Phlegmasia cerulea dolens as a complication of percutaneous insertion of a vena caval filter.股青肿作为经皮插入下腔静脉滤器的一种并发症。
J Am Osteopath Assoc. 1989 Jan;89(1):63-8.
10
Phlegmasia Cerulea Dolens in a Patient with Breast Cancer and Inferior Vena Cava Hypoplasia.一名患有乳腺癌和下腔静脉发育不全患者的股青肿
Case Rep Vasc Med. 2020 Feb 27;2020:2176848. doi: 10.1155/2020/2176848. eCollection 2020.

引用本文的文献

1
Advancing the understanding of the role of apoptosis in lung cancer immunotherapy: Global research trends, key themes, and emerging frontiers.深化对细胞凋亡在肺癌免疫治疗中作用的理解：全球研究趋势、关键主题及新兴前沿
Hum Vaccin Immunother. 2025 Dec;21(1):2488074. doi: 10.1080/21645515.2025.2488074. Epub 2025 Apr 5.
2
Delayed onset phlegmasia cerulea dolens post-SARS-CoV-2 infection treated with minimally invasive clot retrieval technology.采用微创取栓技术治疗新型冠状病毒感染后迟发性股青肿
J Vasc Surg Cases Innov Tech. 2023 Mar;9(1):101082. doi: 10.1016/j.jvscit.2022.11.019. Epub 2022 Dec 17.
3
Phlegmasia Cerulea Dolens Secondary to COVID-19 and May-Thurner Syndrome: A Case Report.

本文引用的文献

1
D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study.D-二聚体作为COVID-19患者疾病严重程度和死亡率的生物标志物：一项病例对照研究。
J Intensive Care. 2020 Jul 10;8:49. doi: 10.1186/s40560-020-00466-z. eCollection 2020.
2
Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review.COVID-19 相关血栓是否由补体级联的过度激活引起？文献综述。
Thromb Res. 2020 Oct;194:36-41. doi: 10.1016/j.thromres.2020.06.027. Epub 2020 Jun 18.
3
Thrombosis and COVID-19 pneumonia: the clot thickens!
新冠病毒感染继发蓝趾综合征伴梅-图二氏综合征：一例报告
Cureus. 2022 Jan 16;14(1):e21301. doi: 10.7759/cureus.21301. eCollection 2022 Jan.
血栓与 COVID-19 肺炎：凝块变厚！
Eur Respir J. 2020 Jul 30;56(1). doi: 10.1183/13993003.01608-2020. Print 2020 Jul.
4
Deep Vein Thrombosis in Hospitalized Patients With COVID-19 in Wuhan, China: Prevalence, Risk Factors, and Outcome.中国武汉 COVID-19 住院患者的深静脉血栓形成：患病率、危险因素和结局。
Circulation. 2020 Jul 14;142(2):114-128. doi: 10.1161/CIRCULATIONAHA.120.046702. Epub 2020 May 18.
5
High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.严重严重急性呼吸综合征冠状病毒 2 型感染患者的血栓形成风险高：一项多中心前瞻性队列研究。
Intensive Care Med. 2020 Jun;46(6):1089-1098. doi: 10.1007/s00134-020-06062-x. Epub 2020 May 4.
6
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.抗凝治疗与伴有凝血功能障碍的严重 2019 冠状病毒病患者的死亡率降低相关。
J Thromb Haemost. 2020 May;18(5):1094-1099. doi: 10.1111/jth.14817. Epub 2020 Apr 27.
7
Wells and Geneva Scores Are Not Reliable Predictors of Pulmonary Embolism in Critically Ill Patients: A Retrospective Study.危重症患者 Wells 和 Geneva 评分不能可靠预测肺栓塞：一项回顾性研究。
J Intensive Care Med. 2020 Oct;35(10):1112-1117. doi: 10.1177/0885066618816280. Epub 2018 Dec 16.
8
Phlegmasia caerulea dolens and venous gangrene.股青肿与静脉性坏疽
Br J Surg. 1996 Jan;83(1):19-23. doi: 10.1002/bjs.1800830106.